Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CXCR3 | P49682 | 10/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888640 | 1.00 | TDP1 (0.52) | TDP1CXCR3CTSSCTSKHDAC8 | |
| SCHEMBL8294401 | 0.95 | TDP1 (0.56) | TDP1CXCR3CTSSCTSKHDAC8 | |
| SCHEMBL6298469 | 0.95 | TDP1 (0.56) | TDP1CXCR3CTSSCTSKHDAC8 | |
| SCHEMBL5223869 | 0.88 | CFD (0.42) | TDP1CTSSCTSKSCN9A | |
| SCHEMBL5223880 | 0.88 | CFD (0.42) | TDP1CTSSCTSKSCN9A | |
| SCHEMBL8294728 | 0.86 | TDP1 (0.48) | TDP1CXCR3CTSSCTSKSCN9A | |
| SCHEMBL6253225 | 0.86 | TDP1 (0.48) | TDP1CXCR3CTSSCTSKSCN9A | |
| SCHEMBL8293690 | 0.85 | TDP1 (0.52) | TDP1CXCR3CTSSCTSKSCN9A | |
| SCHEMBL4886578 | 0.84 | TDP1 (0.55) | TDP1 | |
| SCHEMBL1072034 | 0.84 | TDP1 (0.55) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | TDP1 1568/4885CXCR3 2950/4885CTSS 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.